Sequential treatment in vulvovaginal atrophy.

Area of Science:

• Gynecology
• Women's Health
• Vaginal Health

Background:

• Vulvovaginal atrophy (VVA) is a chronic condition impacting quality of life and sexual health.
• Effective management necessitates long-term, sequential treatment strategies.
• Current treatments include topical products, hormone therapy, DHEA, ospemifene, and energy-based options.

Purpose of the Study:

• To review and categorize current therapeutic options for vulvovaginal atrophy.
• To propose a sequential treatment approach based on efficacy, safety, and patient adherence.
• To highlight the role of estrogen receptor-acting treatments as a primary therapeutic strategy.

Main Methods:

• Literature review of current vulvovaginal atrophy treatments.
• Analysis of treatment mechanisms, efficacy, and safety profiles.
• Development of a tiered treatment recommendation framework.

Main Results:

• Estrogen receptor-targeting treatments are proposed as the first-line option due to physiological benefits and efficacy.
• Vaginal moisturizers are effective for symptom relief but do not address underlying conditions.
• Energy-based treatments (laser, radiofrequency) present a third option, with considerations for cost and long-term safety data.

Conclusions:

• A sequential treatment approach prioritizing estrogen receptor therapies is recommended for vulvovaginal atrophy.
• Vaginal moisturizers and lubricants can be used adjunctively or as alternatives.
• Further research on the long-term safety and cost-effectiveness of energy-based treatments is warranted.